Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2025)

Crinetics Pharmaceuticals has reported Operating Income over the past 9 years, most recently at -$133.7 million for Q4 2025.

  • For Q4 2025, Operating Income fell 41.08% year-over-year to -$133.7 million; the TTM value through Dec 2025 reached -$516.8 million, down 52.5%, while the annual FY2025 figure was -$516.8 million, 52.5% down from the prior year.
  • Operating Income for Q4 2025 was -$133.7 million at Crinetics Pharmaceuticals, up from -$142.6 million in the prior quarter.
  • Over five years, Operating Income peaked at -$22.9 million in Q1 2021 and troughed at -$142.6 million in Q3 2025.
  • A 5-year average of -$67.7 million and a median of -$56.0 million in 2023 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: tumbled 64.99% in 2022 and later fell 23.12% in 2023.
  • Year by year, Operating Income stood at -$30.9 million in 2021, then plummeted by 53.96% to -$47.6 million in 2022, then tumbled by 31.76% to -$62.7 million in 2023, then tumbled by 51.21% to -$94.7 million in 2024, then plummeted by 41.08% to -$133.7 million in 2025.
  • Business Quant data shows Operating Income for CRNX at -$133.7 million in Q4 2025, -$142.6 million in Q3 2025, and -$129.1 million in Q2 2025.